All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Johnson & Johnson, Syndax, Thermo Fisher Scientific, Kura Oncology, AbbVie, and has been supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group.
The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View AML content recommended for you
ASH 2025 | Top abstracts: What’s hot in acute myeloid leukemia?
To help navigate the exciting content being presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, December 6–9, 2025, Orlando, US, the AML Hub Steering Committee members have provided their recommendations for the top abstracts to look out for in acute myeloid leukemia.
Oral presentations: Saturday, December 6
| Abstract | Title | Presenter | Time (EST) |
| 42 | Outcomes of patients with relapsed/refractory FLT3mut+ acute myeloid leukemia who resumed gilteritinib therapy after HSCT: Post hoc analysis from the ADMIRAL and COMMODORE trials | Jianxiang Wang | 10:45–11:00 |
| 45 | Long-term follow-up of azacitidine, venetoclax, and gilteritinib in patients with newly diagnosed FLT3-mutated acute myeloid leukemia | Roberta S Azevedo | 10:00–10:15 |
| 47 | Phase II study of the all-oral combination of revumenib (SNDX-5613) with decitabine/cedazuridine (ASTX727) and venetoclax (SAVE) in newly diagnosed AML | Wei-Ying Jen | 10:30–10:45 |
| 109 | Superior long-term outcomes with fludarabine and melphalan reduced intensity regimen in older AML/MDS patients undergoing allogeneic stem cell transplantation: An analysis of CIBMTR data | Piyanuch Kongtim | 09:30–09:45 |
| 110 | Addition of thiotepa to a busulphan based conditioning regimen does not improve survival in patients allografted for acute myeloid leukaemia and myelodysplasia: Results of the UK impact COSI trial | Charles Craddock | 09:45–10.00 |
| 170 | Effect of FLT3 maintenance in older FLT3-ITD+ adults undergoing allogeneic HCT. A post hoc analysis of BMT CTN 1506 | Sameem Abedin | 12:15–12:30 |
| 344 | Prospective assessment of measurable residual disease kinetics in intensively treated patients with acute myeloid leukemia (AML) - results of the PALG-AML1/2016 study | Agnieszka Wierzbowska | 16:15–16:30 |
| 345 | FLT3-ITD NGS-MRD refines risk stratification in NPM1 and FLT3 co-mutated AML beyond NPM1 PCR-MRD: Analysis of the UK NCRI AML17 and AML19 trials | Aditya Tedjaseputra | 16:30–16:45 |
Oral presentations: Sunday, December 7
| Abstract | Title | Presenter | Time (EST) |
| 6 | Results from PARADIGM - a phase 2 randomized multi-center study comparing azacitidine and venetoclax to conventional induction chemotherapy for newly diagnosed fit adults with acute myeloid leukemia | Amir Fathi | 15:45–16:00 |
| 652 | γ9δ2 T-cell (γ9δ2TC) activation with ICT01 and azacitidine-venetoclax (Aza-Ven) induces high rates of remission and overall survival in patients with newly diagnosed (ND) acute myeloid leukemia (AML): Results from the phase 1/2 study EVICTION | Sylvain Garciaz | 17:15–17:30 |
| 654 | Venetoclax (VEN) and azacitidine (AZA) with gilteritinib (GILT) in patients with newly diagnosed (ND) FLT3mut+ acute myeloid leukemia (AML) ineligible for intensive induction chemotherapy (chemo): Interim results from the phase 1/2 VICEROY study | Jessica Altman | 17:45–18:00 |
Oral presentations: Monday, December 8
| Abstract | Title | Presenter | Time (EST) |
| 763 | Monotherapy update from phase 1 portion in phase 1/2 trial of the menin-MLL inhibitor enzomenib (DSP-5336) in patients with relapsed or refractory acute leukemia | Naval Daver | 10:30–10:45 |
| 764 | Ziftomenib in combination with venetoclax and azacitidine in relapsed/refractory NPM1-m or KMT2A-r acute myeloid leukemia: Updated phase 1a/b safety and clinical activity results from KOMET-007 | Amir Fathi | 11:45–12:00 |
| 765 | Preliminary data from the ongoing phase 1 study of the menin-MLL inhibitor enzomenib (DSP-5336) in combination with venetoclax and azacitidine in patients with relapsed or refractory acute myeloid leukemia | Justin Watts | 11:00–11:15 |
| 766 | Ziftomenib in combination with venetoclax and azacitidine in newly diagnosed NPM1-m acute myeloid leukemia: Phase 1b results from KOMET-007 | Gail Roboz | 11:15–11:30 |
| 767 | Crenolanib plus salvage chemotherapy improves outcomes in FLT3-mutant and NPM1 co-mutated relapsed/ refractory (R/R) acute myeloid leukemia (AML): Results from a randomized, placebo-controlled, double-blind trial | Thomas Cluzeau | 11:30–11:45 |
| 768 | Preliminary anti-leukemia activity from a phase 1 study of CLN-049, a novel anti-FLT3 x anti-CD3 bispecific T-cell engager, in relapsed/refractory (R/R) acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) | Maher Abdul-Hay | 10:45–11:00 |
| 992 | Updated response and safety analyses from a phase 1 study of ivosidenib combined with intensive chemotherapy in patients with newly diagnosed (ND) acute myeloid leukemia with isocitrate dehydrogenase (IDH)1 mutation | Eytan Stein | 16:45–17:00 |
Posters
| Abstract | Title | Presenter | Time (EST) |
| 1507 | PPM1D mutations confer resistance to venetoclax in pre-leukemic and AML populations | Jules Higue | Saturday, December 6, 17:30–19:30 |
| 1662 | Real-world effectiveness of gilteritinib beyond second-line therapy in relapsed/refractory FLT3-mutated acute myeloid leukemia: A European multicenter study of 171 patients | Matteo Molica | Saturday, December 6, 17:30–19:30 |
| 2650 | Healthcare resource utilization in patients receiving quizartinib or placebo in combination with chemotherapy for newly diagnosed, FLT3-ITD+ acute myeloid leukemia: An analysis from the QuANTUM-first trial | Harry Erba | Saturday, December 6, 17:30–19:30 |
| 3428 | Phase l dose escalation and expansion of ziftomenib in combination with quizartinib in AML | Ghayas Issa | Sunday, December 7, 18:00–20:00 |
| 3439 | Analysis of hematologic improvement (HI) by time to response in relapsed/refractory acute myeloid leukemia (AML) patients treated with olutasidenib | Eunice Wang | Sunday, December 7, 18:00–20:00 |
| 3440 | CYP3A4 inhibitors (CYP3A4i) and myelosuppression in patients (pts) with newly diagnosed mutant isocitrate dehydrogenase 1 (mIDH1) acute myeloid leukemia (AML) in the phase 3 AGILE study | Andre Schuh | Sunday, December 7, 18:00–20:00 |
| 3443 | ALIDHE: An ongoing open-label phase 3b study investigating ivosidenib with azacitidine in clinical practice in adult patients with newly diagnosed mutant isocitrate dehydrogenase 1 (mIDH1) acute myeloid leukemia (AML) ineligible for intensive induction chemotherapy (IC) | Paresh Vyas | Sunday, December 7, 18:00–20:00 |
| 3465 | Identifying patients at risk of prolonged neutropenia and enhanced risk of complications during AZA-VEN induction for AML | Jules Higue | Sunday, December 7, 18:00–20:00 |
| 5067 | A randomized placebo-controlled phase 1 trial in healthy volunteers investigating safety, pharmacokinetics and pharmacodynamics of a novel menin inhibitor, balomenib (ZE63-0302): Interim analysis | Amy Burd | Monday, December 8, 18:00–20:00 |
| 5215 | Effectiveness and safety of CPX-351 in younger patients <60 years with newly diagnosed secondary acute myeloid leukemia: Pooled analysis of US (V-RULES) and UK (CREST-UK) real-world studies | Thomas LeBlanc | Monday, December 8, 18:00–20:00 |
| 5226 | A phase II study of azacitidine, venetoclax, and gilteritinib for newly diagnosed adverse risk FLT3-wild type acute myeloid leukemia | Sankalp Arora | Monday, December 8, 18:00–20:00 |
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content